MOESM1 of Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial

Palma, David; Chen, Hanbo; Bahig, Houda; Gaede, Stewart; Harrow, Stephen; Laba, Joanna; Qu, X.; Rodrigues, George; Yaremko, Brian P.; Yu, Edward; Louie, Alexander; Dhaliwal, Inderdeep; Ryerson, Christopher

doi:10.6084/m9.figshare.11358152.v1

12885_2019_6392_MOESM1_ESM.docx (16.79 kB)

MOESM1 of Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial

journal contribution

posted on 2019-12-12, 12:11 authored by David Palma, Hanbo Chen, Houda Bahig, Stewart Gaede, Stephen Harrow, Joanna Laba, X. Qu, George Rodrigues, Brian P. Yaremko, Edward Yu, Alexander Louie, Inderdeep Dhaliwal, Christopher Ryerson

Additional file 1. Â Summary of SABR-related mortality and ILD-specific toxicity. Reproduced from Chen et al [10].

Funding

Ontario Institute for Cancer Research

History

Usage metrics

Keywords

Stereotactic radiotherapy Cancer Lung Interstitial lung disease Toxicity Survival

Licence

CC BY + CC0

MOESM1 of Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): study protocol for a phase II trial

Funding

Ontario Institute for Cancer Research

History

Usage metrics

Categories

Keywords

Licence

Exports